dorsaVi Evaluates Upscaling Motion Sensor Technology to Deliver Better Outcomes at Smaller Scale

dorsaVi (ASX: DVL) has embarked on a formal evaluation program to upscale its oxide-based resistive random access memory from 40 nanometers to an advanced 22nm process node.
IC
Imelda Cotton
·1 min read
dorsaVi Evaluates Upscaling Motion Sensor Technology to Deliver Better Outcomes at Smaller Scale

Wearable sensor technology developer ++dorsaVi (ASX: DVL)++ has embarked on a formal evaluation program to upscale its oxide-based resistive random access memory (RRAM) from 40 nanometers to an advanced 22nm process node.

The evaluation will build on strong device and wafer-level results at 40nm and focus on the performance, density, and manufacturing benefits of migrating the RRAM architecture to 22nm.

Working with Singapore’s Nanyang Technological University and its own fabrication intermediary, dorsaVi will model how the upscaling affects device-level cells and array-level behaviour such as latency, energy/bit, variability, and uniformity.

The company expects that advancing to a 22nm RRAM implementation will allow its motion-sensor technology to deliver better outcomes at a smaller scale.

Higher Density, Lower Energy

dorsaVi’s evaluation will aim to deliver higher density and lower energy, as well as faster switching between speeds of 50 nanoseconds to 200ns for its wearables technology, promoting real-time biosignal processing and always-on motion intelligence.

The upscaling gains are intended to relieve NAND bottlenecks, extend device battery life and enable tighter closed-loop responsiveness in edge workloads.

Clients can expect more responsive analytics and longer wear times in lighter, slimmer devices, supporting cleaner electromyography/electrocardiogram (EMG/ECG) capture, faster objective reporting, and simpler clinic workflows.

The 22nm RRAM evaluation signals dorsaVi’s continued focus on longer wear times, faster objective reporting, and smaller devices utilising its ViMove+ advanced movement analysis technology.

Physical Therapy Uptake

dorsaVi reported last month that ViMove+ had shown a “phenomenal early growth trajectory” in the prized US physical therapy market, with growth rates tracking 15x higher than historical monthly acquisition trends and each clinic delivering a consistent annual recurring revenue of $3,000.

The market comprises 66,000 clinics across the US and remains relatively unpenetrated for objective movement analysis products.

The company expects the RRAM evaluation to enable ViMove+ to remain best-in-class as the technology’s rollout expands across the entire network.

Over the longer term, the improvements will strengthen compute-near-memory and robotics reflex functions being advanced by ++dorsaVi subsidiary Artemis Labs++.

Stay Informed

Get the latest ASX small-cap news, exclusive interviews, and market insights delivered to your inbox weekly.

Join 100,000+ investors. Unsubscribe anytime.

More Like This

View All